The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT)
C. Jillian Tsai, Lead, Allan and Ruth Kerbel Palliative Radiotherapy and Oligometastasis Program at Princess Margaret Cancer Centre, shared an article by Rachel M. Glicksman on LinkedIn:
“Congrats to Rachel Glicksman and the team Radiation Medicine Program, RMP Clinical Research Program and Princess Margaret Cancer Centre for publishing this Ph2 single arm study of SBRT for OPD.
- 1yr PFS 32%; median 4.7mo overall, different by histology.
- 1 patient had Gr3 tox; overall very well tolerated.
- No significant decline in QOL.
The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial – International Journal of Radiation Oncology, Biology, Physics.”
The Role of Stereotactic Body Radiotherapy in Oligoprogressive Malignant Disease (RADIANT): Oncologic Outcomes From a Phase 2 Nonrandomized Controlled Trial.
Authors: Rachel M. Glicksman, et al.
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology at UCLA, reshared the post on X:
“SBRT helps avoid SYSTEMIC THERAPY INTENSIFICATION in 50% of patients with stage IV cancer without any serious side effects in 99%.
Name a single drug that can accomplish this.I’ll wait….Jill Feldman.”
Dr. Drew Moghanaki is a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university. He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023